AGEN Long Call Strategy
AGEN (Agenus Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation.
AGEN (Agenus Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $126.2M, a trailing P/E of 1.78, a beta of 1.54 versus the broader market, a 52-week range of 2.71-7.34, average daily share volume of 847K, a public-listing history dating back to 2000, approximately 316 full-time employees. These structural characteristics shape how AGEN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.54 indicates AGEN has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position. The trailing P/E of 1.78 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.
What is a long call on AGEN?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current AGEN snapshot
As of June 30, 2026, spot at $3.06, ATM IV 79.70%, IV rank 13.48%, expected move 22.85%. The long call on AGEN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this long call structure on AGEN specifically: AGEN IV at 79.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a AGEN long call, with a market-implied 1-standard-deviation move of approximately 22.85% (roughly $0.70 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated AGEN expiries trade a higher absolute premium for lower per-day decay. Position sizing on AGEN should anchor to the underlying notional of $3.06 per share and to the trader's directional view on AGEN stock.
AGEN long call setup
The AGEN long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With AGEN near $3.06, the first option leg uses a $3.06 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed AGEN chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 AGEN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $3.06 | N/A |
AGEN long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
AGEN long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on AGEN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on AGEN
Long calls on AGEN express a bullish thesis with defined risk; traders use them ahead of AGEN catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
AGEN thesis for this long call
The market-implied 1-standard-deviation range for AGEN extends from approximately $2.36 on the downside to $3.76 on the upside. A AGEN long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current AGEN IV rank near 13.48% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on AGEN at 79.70%. As a Healthcare name, AGEN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to AGEN-specific events.
AGEN long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. AGEN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move AGEN alongside the broader basket even when AGEN-specific fundamentals are unchanged. Long-premium structures like a long call on AGEN are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current AGEN chain quotes before placing a trade.
Frequently asked questions
- What is a long call on AGEN?
- A long call on AGEN is the long call strategy applied to AGEN (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With AGEN stock trading near $3.06, the strikes shown on this page are snapped to the nearest listed AGEN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are AGEN long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the AGEN long call priced from the end-of-day chain at a 30-day expiry (ATM IV 79.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a AGEN long call?
- The breakeven for the AGEN long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current AGEN market-implied 1-standard-deviation expected move is approximately 22.85%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on AGEN?
- Long calls on AGEN express a bullish thesis with defined risk; traders use them ahead of AGEN catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current AGEN implied volatility affect this long call?
- AGEN ATM IV is at 79.70% with IV rank near 13.48%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.